Luly Jay R.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Feb 12, 2025
- Accession no.
- 0001062993-25-002225
- Filed
- Feb 12, 2025
- Trade date
- Feb 12, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $256.1K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luly Jay R.CIK 0001571211 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | Common Stock | PPurchaseAcquired | +45,000 | $5.69 | +$256,050 | 846,638 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.